Device Trial Radar · NCT02158078
A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Jul 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8
Actual
Start
Jun 2014
Primary completion
Nov 2014
Study completion Nov 2014
Sponsor
- Lead sponsor
- CeQur CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 6, 2014
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).
Conditions
- Type 2 Diabetes Mellitus
Interventions
PaQ® Insulin Delivery DeviceDevice
PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood) from baseline at Week 12Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of Graz
Graz, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.